Publications by authors named "Luna Musib"

Claim this Profile
M
Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects.
Smita Kshirsagar, Ya-Chi Chen, Jiajie Yu, Mary R Gates, Sonoko Kawakatsu, Luna Musib

Drug Metab Dispos· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Ryan H Takahashi, Vikram Malhi, Bianca M Liederer, Sungjoon Cho, Yuzhong Deng, Luna Musib

Drug Metab Dispos· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Rethink the Current Paradigm for Assessing Kidney Function in Drug Development and Beyond.
Ashish Sharma, Vaishali Sahasrabudhe, Luna Musib, Steven Zhang, Islam Younis

Clin Pharmacol Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing Jing, Yuan Chen, Luna Musib, Jin Y Jin, Kit Wun Kathy Cheung

Cancer Chemother Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Tanya Trippett, Helen Toledano, Quentin Campbell Hewson, Arnauld Verschuur, Anne-Marie Langevin, Luna Musib

Target Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
Rucha Sane, Vikram Malhi, Dhruvitkumar S Sutaria, Eunpi Cho, Patrick Twomey, Luna Musib

J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib.
Vikram Malhi, Nageshwar Budha, Rucha Sane, Jian Huang, Bianca Liederer, Luna Musib

Cancer Chemother Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects.
Rucha S Sane, Kit Wun Kathy Cheung, Eunpi Cho, Bianca M Liederer, Justin Hanover, Luna Musib

J Pharmacol Exp Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Pascal Chanu, Luna Musib, Xin Wang, Sravanthi Cheeti, Sandhya Girish

J Invest Dermatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Sravanthi Cheeti, Yuzhong Deng, Ilsung Chang, Isabela Georgescu, Ian Templeton, Luna Musib

Clin Pharmacol Drug Dev· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, Luna Musib, Yibing Yan

Invest New Drugs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Rucha Sane, Kit Wun Kathy Cheung, Péter Kovács, Taleah Farasyn, Ruina Li, Luna Musib

Drug Metab Dispos· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Geoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, Susan Pandya, Charles M Rudin, Luna Musib

Invest New Drugs· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
Rui Zhu, Bill Poland, Russ Wada, Qi Liu, Luna Musib

CPT Pharmacometrics Syst Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Sravanthi Cheeti, Hao Helen Hou, Eric Nelson, Helen Walker, Buyun Chen, Luna Musib

Pharm Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Sravanthi Cheeti, Hao Helen Hou, Eric Nelson, Helen Walker, Buyun Chen, Luna Musib

Pharm Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Jennifer L McQuade, Carrie R Daniel, Kenneth R Hess, Carmen Mak, Daniel Y Wang, Luna Musib

Lancet Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Dose Selection and Utility of PBPK in Determining Dose.
Ian E Templeton, Nicholas S Jones, Luna Musib

AAPS J· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Cristina Saura, Desamparados Roda, Susana Roselló, Mafalda Oliveira, Teresa Macarulla, Luna Musib

Cancer Discov· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Nageshwar R Budha, Tao Ji, Luna Musib, Steve Eppler, Mark Dresser

Clin Pharmacokinet· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
Dan Lu, Tong Lu, Mark Stroh, Richard A Graham, Priya Agarwal, Luna Musib

Cancer Chemother Pharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
Pamela A Welch, Wee Teck Ng, Christelle L Darstein, Luna Musib, Thierry Lesimple

J Clin Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Ryan H Takahashi, Edna F Choo, Shuguang Ma, Susan Wong, Jason Halladay, Luna Musib

Drug Metab Dispos· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Kelong Han, Jin Y Jin, Mathilde Marchand, Stephen Eppler, Nicholas Choong, Luna Musib

Cancer Chemother Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK inhibitors beyond monotherapy: current and future development.
Ian E Templeton, Luna Musib

Curr Opin Pharmacol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis